Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bergamaschi

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Journal of Psychopharmacology (Oxford, England)|September 20, 2014
Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trialMarcos Hortes N Chagas, Antonio W Zuardi, Vitor Tumas, et al.
Annals of Hematology|November 8, 2015
The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemiaF Efficace, G Rosti, M Breccia, et al.
Journal of Clinical Pharmacy and Therapeutics|May 22, 2014
Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case seriesM H N Chagas, A L Eckeli, A W Zuardi, et al.
Physical Review Letters|August 18, 2018
Direct Observation of Incoherent Cherenkov Diffraction Radiation in the Visible RangeR Kieffer, L Bartnik, M Bergamaschi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 11, 2011
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patientsMateus M Bergamaschi, Regina Helena Costa Queiroz, Marcos Hortes Nisihara Chagas, et al.
Human Psychopharmacology|January 16, 2014
Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary reportMateus M Bergamaschi, Regina H C Queiroz, Marcos H N Chagas, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 2010
Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonistG Villetti, F Pastore, M Bergamaschi, et al.
Leukemia|February 19, 2013
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinibF Efficace, M Baccarani, M Breccia, et al.
Leukemia Research|July 7, 2015
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromesE Balleari, C Salvetti, L Del Corso, et al.
Blood Cancer Journal|September 19, 2015
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatmentD Russo, M Malagola, C Skert, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Journal of Psychopharmacology (Oxford, England)|September 20, 2014
Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trialMarcos Hortes N Chagas, Antonio W Zuardi, Vitor Tumas, et al.
Annals of Hematology|November 8, 2015
The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemiaF Efficace, G Rosti, M Breccia, et al.
Journal of Clinical Pharmacy and Therapeutics|May 22, 2014
Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case seriesM H N Chagas, A L Eckeli, A W Zuardi, et al.
Physical Review Letters|August 18, 2018
Direct Observation of Incoherent Cherenkov Diffraction Radiation in the Visible RangeR Kieffer, L Bartnik, M Bergamaschi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 11, 2011
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patientsMateus M Bergamaschi, Regina Helena Costa Queiroz, Marcos Hortes Nisihara Chagas, et al.
Human Psychopharmacology|January 16, 2014
Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary reportMateus M Bergamaschi, Regina H C Queiroz, Marcos H N Chagas, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 2010
Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonistG Villetti, F Pastore, M Bergamaschi, et al.
Leukemia|February 19, 2013
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinibF Efficace, M Baccarani, M Breccia, et al.
Leukemia Research|July 7, 2015
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromesE Balleari, C Salvetti, L Del Corso, et al.
Blood Cancer Journal|September 19, 2015
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatmentD Russo, M Malagola, C Skert, et al.
Pageof 9